FindTrial
Sign In

PD0332991

DRUG5 trials

Sponsors

University of Florida, Abramson Cancer Center at Penn Medicine, Jonsson Comprehensive Cancer Center, Washington University School of Medicine, Gustave Roussy, Cancer Campus, Grand Paris

Conditions

Breast CancerBreast NeoplasmsNon-small Cell Lung CancerOvarian Epithelial CarcinomaUntreated Operable Early Breast Cancer

Phase 1

PD0332991/Paclitaxel in Advanced Breast Cancer
CompletedNCT01320592
Abramson Cancer Center at Penn MedicineBreast Cancer
Start: 2011-03-31End: 2019-05-31Updated: 2020-04-08

Phase 2

Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.
CompletedNCT01291017
University of FloridaNon-small Cell Lung Cancer
Start: 2011-02-28End: 2015-02-28Updated: 2016-05-13
A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression
CompletedNCT01536743
Jonsson Comprehensive Cancer CenterOvarian Epithelial Carcinoma
Start: 2011-12-15End: 2020-02-24Updated: 2020-06-05
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Active, not recruitingNCT01723774
Washington University School of MedicineBreast Neoplasms
Start: 2013-04-10End: 2026-08-24Updated: 2025-12-09
Randomized Phase II Study to Assess PD 0332991 in Breast Cancer
CompletedNCT02008734
Gustave Roussy, Cancer Campus, Grand ParisUntreated Operable Early Breast Cancer
Start: 2014-01-31End: 2016-01-31Updated: 2016-06-09

Related Papers

Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial.
2026-01-27
Abstract PS12-03: Molecular characterization of the NeoPalAna Endocrine Resistant (ET-R) Cohort: implications for CDK4/6 inhibitor (CDK4/6i) and ET resistance mechanisms in primary estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC)
Clinical Cancer Research2025-06-13
Abstract P2-03-29: Upregulation of senescence signatures and interferon-signalling after short-term pre-operative CDK4/6 inhibitor – gene expression analysis from the POP and ABC-POP trials
Clinical Cancer Research2025-06-13
Abstract P1-03-20: Role of MCM2 and the licensing complex in predicting endocrine and CDK4/6 inhibitor resistance in ER+ breast cancer
Clinical Cancer Research2025-06-13
Abstract P5-13-20: Identifying a metabolite signature that correlates with tumor proliferation in early-stage breast cancer patients treated with CDK4/6 inhibitors from matched plasma and serum samples
Cancer Research2022-02-15
Abstract GS2-01: High levels of interferon-response gene signatures are associated with <i>de novo</i> and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer
Cancer Research2020-02-153 citations
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
Journal of Clinical Oncology2019-02-26435 citations
Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer
Clinical Cancer Research2019-01-1145 citations
Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial
Annals of Oncology2018-06-0761 citations
Abstract P2-09-16: Tumor infiltrating lymphocytes (TILs) as a biomarker for resistance to palbociclib (Pal) in the NeoPalAna trial
Cancer Research2018-02-15
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
2017-11-2151 citations
Phase II trial of neoadjuvant (neo) palbociclib (Palbo) plus anastrozole (ana) in endocrine resistant clinical stage 2/3 estrogen receptor positive and HER2 negative (ER+ HER2-) breast cancer (BC).
Journal of Clinical Oncology2017-05-20
A multicenter open-label phase II study of the efficacy and safety of palbociclib a cyclin-dependent kinases 4 and 6 inhibitor in patients with recurrent ovarian cancer.
Journal of Clinical Oncology2016-05-2029 citations
A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated <i>CDKN2A</i>.
Journal of Clinical Oncology2014-05-2048 citations
A phase I trial of palbociclib and paclitaxel in metastatic breast cancer.
Journal of Clinical Oncology2014-05-2017 citations